Cargando…
Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? the REACT study protocol
BACKGROUND: Many patients with chronic obstructive pulmonary disease (COPD) continue to suffer exacerbations, even when treated with maximum recommended therapy (eg, inhaled combinations of long-acting β(2)-agonist and high dose inhaled corticosteroids, with or without a long-acting anticholinergic...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3393336/ https://www.ncbi.nlm.nih.gov/pubmed/22791991 http://dx.doi.org/10.2147/COPD.S31100 |
_version_ | 1782237725835919360 |
---|---|
author | Calverley, Peter MA Martinez, Fernando J Fabbri, Leonardo M Goehring, Udo-Michael Rabe, Klaus F |
author_facet | Calverley, Peter MA Martinez, Fernando J Fabbri, Leonardo M Goehring, Udo-Michael Rabe, Klaus F |
author_sort | Calverley, Peter MA |
collection | PubMed |
description | BACKGROUND: Many patients with chronic obstructive pulmonary disease (COPD) continue to suffer exacerbations, even when treated with maximum recommended therapy (eg, inhaled combinations of long-acting β(2)-agonist and high dose inhaled corticosteroids, with or without a long-acting anticholinergic [long-acting muscarinic antagonist]). Roflumilast is approved to treat severe COPD in patients with chronic bronchitis – and a history of frequent exacerbations – as an add-on to bronchodilators. PURPOSE: The REACT (Roflumilast in the Prevention of COPD Exacerbations While Taking Appropriate Combination Treatment) study (identification number RO-2455-404-RD, clinicaltrials. gov identifier NCT01329029) will investigate whether roflumilast further reduces exacerbations when added to inhaled combination therapy in patients still suffering from frequent exacerbations. PATIENTS AND METHODS: REACT is a 1-year randomized, double-blind, multicenter, phase III/IV study of roflumilast 500 μg once daily or placebo on top of a fixed long-acting β(2)-agonist/inhaled corticosteroid combination. A concomitant long-acting muscarinic antagonist will be allowed at stable doses. The primary outcome is the rate of moderate or severe COPD exacerbations. Using a Poisson regression model with a two-sided significance level of 5%, a sample size of 967 patients per treatment group is needed for 90% power. COPD patients with severe to very severe airflow limitation, symptoms of chronic bronchitis, and at least two exacerbations in the previous year will be recruited. CONCLUSION: It is hypothesized that because roflumilast (a phosphodiesterase-4 inhibitor) has a different mode of action to bronchodilators and inhaled corticosteroids, it may provide additional benefits when added to these treatments in frequent exacerbators. REACT will be important to determine the role of roflumilast in COPD management. Here, the design and rationale for this important study is described. |
format | Online Article Text |
id | pubmed-3393336 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-33933362012-07-12 Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? the REACT study protocol Calverley, Peter MA Martinez, Fernando J Fabbri, Leonardo M Goehring, Udo-Michael Rabe, Klaus F Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: Many patients with chronic obstructive pulmonary disease (COPD) continue to suffer exacerbations, even when treated with maximum recommended therapy (eg, inhaled combinations of long-acting β(2)-agonist and high dose inhaled corticosteroids, with or without a long-acting anticholinergic [long-acting muscarinic antagonist]). Roflumilast is approved to treat severe COPD in patients with chronic bronchitis – and a history of frequent exacerbations – as an add-on to bronchodilators. PURPOSE: The REACT (Roflumilast in the Prevention of COPD Exacerbations While Taking Appropriate Combination Treatment) study (identification number RO-2455-404-RD, clinicaltrials. gov identifier NCT01329029) will investigate whether roflumilast further reduces exacerbations when added to inhaled combination therapy in patients still suffering from frequent exacerbations. PATIENTS AND METHODS: REACT is a 1-year randomized, double-blind, multicenter, phase III/IV study of roflumilast 500 μg once daily or placebo on top of a fixed long-acting β(2)-agonist/inhaled corticosteroid combination. A concomitant long-acting muscarinic antagonist will be allowed at stable doses. The primary outcome is the rate of moderate or severe COPD exacerbations. Using a Poisson regression model with a two-sided significance level of 5%, a sample size of 967 patients per treatment group is needed for 90% power. COPD patients with severe to very severe airflow limitation, symptoms of chronic bronchitis, and at least two exacerbations in the previous year will be recruited. CONCLUSION: It is hypothesized that because roflumilast (a phosphodiesterase-4 inhibitor) has a different mode of action to bronchodilators and inhaled corticosteroids, it may provide additional benefits when added to these treatments in frequent exacerbators. REACT will be important to determine the role of roflumilast in COPD management. Here, the design and rationale for this important study is described. Dove Medical Press 2012 2012-06-20 /pmc/articles/PMC3393336/ /pubmed/22791991 http://dx.doi.org/10.2147/COPD.S31100 Text en © 2012 Calverley et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Original Research Calverley, Peter MA Martinez, Fernando J Fabbri, Leonardo M Goehring, Udo-Michael Rabe, Klaus F Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? the REACT study protocol |
title | Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? the REACT study protocol |
title_full | Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? the REACT study protocol |
title_fullStr | Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? the REACT study protocol |
title_full_unstemmed | Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? the REACT study protocol |
title_short | Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? the REACT study protocol |
title_sort | does roflumilast decrease exacerbations in severe copd patients not controlled by inhaled combination therapy? the react study protocol |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3393336/ https://www.ncbi.nlm.nih.gov/pubmed/22791991 http://dx.doi.org/10.2147/COPD.S31100 |
work_keys_str_mv | AT calverleypeterma doesroflumilastdecreaseexacerbationsinseverecopdpatientsnotcontrolledbyinhaledcombinationtherapythereactstudyprotocol AT martinezfernandoj doesroflumilastdecreaseexacerbationsinseverecopdpatientsnotcontrolledbyinhaledcombinationtherapythereactstudyprotocol AT fabbrileonardom doesroflumilastdecreaseexacerbationsinseverecopdpatientsnotcontrolledbyinhaledcombinationtherapythereactstudyprotocol AT goehringudomichael doesroflumilastdecreaseexacerbationsinseverecopdpatientsnotcontrolledbyinhaledcombinationtherapythereactstudyprotocol AT rabeklausf doesroflumilastdecreaseexacerbationsinseverecopdpatientsnotcontrolledbyinhaledcombinationtherapythereactstudyprotocol |